Peru's Medical Cannabis Export Push: Big Potential, Small Numbers So Far
Photo by Gabriel Istvan via Unsplash.
Walk into a pharmacy in Lima's Miraflores district and you might find a bottle of Peruvian-made CBD oil sitting on the shelf, a fully packaged, sanitary-registered product rather than a prescription mixed to order behind a counter. That distinction is the whole story of Peru's cannabis policy since November 2017, when Law 30681 made Peru one of the first countries in South America to build a legal framework around finished medical cannabis products rather than just raw plant material or patient-specific compounds. Colombia, Peru's larger and louder regional competitor, restricts its market to "formulas magistrales," individually compounded prescriptions assembled per patient. Peru went a different route, and on paper that gives it a real structural head start toward becoming an export platform for the kind of packaged, shelf-ready cannabis products that move efficiently through international trade.
But paper and practice are different things. The most current licensing data from DIGEMID, Peru's health products regulator, updated as of March 2026, shows a domestic system that is still remarkably small: two active production laboratories, 45 licensed pharmacies, and a patient access rate hovering around 34 percent of registered users. Nearly nine years after the law passed, Peru has built a regulatory architecture sophisticated enough to support real exports, but has not yet built the industry to fill it. That gap between what the rules allow and what actually exists on the ground is the real story here, and it's worth understanding before anyone repeats the export-hub talk that's circulated since 2019.
The Legal Foundation: Law 30681 and Supreme Decree 004-2023-SA
Photo by Felix-Mittermeier via Pixabay.
Law No. 30681, commonly called the Cannabis Law, cleared Peru's Congress in November 2017 and established the basic legal permission structure still in force today: individuals and legal entities may use, research, produce, import, and commercialize cannabis and its derivatives, but strictly for medical and therapeutic purposes. There's no recreational carve-out anywhere in the statute, and there wasn't meant to be one. The law was written as a medical access bill first, with export potential as a secondary, largely unstated consequence of allowing commercial-scale production at all.
The original text left gaps in implementation, which is why Law 31312 came along later to expand its scope and clarify how the licensing and oversight mechanisms were actually supposed to function. Those clarifications set the stage for the regulation that governs the sector today: Supreme Decree 004-2023-SA, published May 28, 2023. This decree is the operative set of lineamientos, the detailed rules covering how licenses get issued, how medical use is documented, and critically, how exportation is supposed to work in practice. It's the document that turns the 2017 law's broad permissions into something a regulator can actually administer.
DIGEMID, the Directorate General of Medicines, Supplies and Drugs operating under MINSA, Peru's health ministry, is the licensing authority handling nearly every step: product registration, manufacturing licenses, import authorizations, and sanitary approvals. For a shipment to legally leave Peru, a manufacturer needs DIGEMID authorization, a valid sanitary registration for the specific product, and documentation proving compliance with Good Manufacturing Practice standards. Only after clearing those hurdles does a shipment move to INPE and SUNAT, Peru's customs authority, for final clearance. It's a multi-agency process, and each layer is a place where a shipment can stall if paperwork isn't in order.
What the Licensing Numbers Actually Show
Despite 55,000 registered medical cannabis users in Peru, only about 18,837 (roughly one-third) actually have product access, highlighting a major supply bottleneck reflected in the mere 45 authorized pharmacies and just 2 active production labs nationwide.
Numbers tell this story better than rhetoric does, and DIGEMID's own database, current as of March 18, 2026, is fairly stark. Just two laboratories hold active authorization to produce cannabis derivatives for medical use in Peru. Add to that one active artisanal-production association and one additional institution whose license is currently listed as inactive, and that's the entire production side of the country's legal cannabis industry as it stands right now.
The retail and access side is somewhat broader but still modest. Forty-five pharmacies hold sales licenses, with 44 of them currently active, and DIGEMID's records show this pharmacy network clustered heavily around Lima rather than distributed nationally. On the import and commercialization side, there are 34 licensed laboratories and droguerías, the wholesale entities that handle distribution of pharmaceutical products, authorized to bring cannabis derivatives into the country and move them through the supply chain.
Then there's the patient number, which is arguably the most telling figure in the whole dataset. More than 55,000 people are registered nationally as cannabis users under the medical program. But only 18,837 of them, roughly 34 percent, have actually acquired product through an authorized establishment. That means two-thirds of the people who've gone through the registration process still haven't gotten their hands on legal medical cannabis.
This access gap isn't just a domestic patient-care problem, it's directly relevant to the export conversation. A country can't credibly position itself as a regional supplier of finished cannabis products while its own registered patients are going without. Thin domestic supply chains mean there's little surplus manufacturing capacity sitting idle and ready to be redirected toward export orders. Whatever export ambitions exist have to compete with unmet local demand for the same limited output of two active labs.
Why Peru's Model Is Structurally Built for Export
Photo by garten-gg via Pixabay.
The structural case for Peru as an export platform rests on one specific regulatory choice: Peru allows finished, consumer-ready cannabis products, not just compounded prescriptions built individually for each patient. Colombia's system, by contrast, restricts commercial activity to formulas magistrales, meaning every product is essentially custom-made per patient rather than manufactured, packaged, and sold as a standardized SKU. That's a meaningful difference for anyone thinking about exports, because standardized packaged goods can be produced at scale, batch-tested once, and shipped in volume. Compounded formulas can't scale the same way; they're inherently bespoke.
Peru's law gives manufacturers that scale advantage on paper. It also draws a firm line around who can bring product into the country: personal importation by individual patients is explicitly not permitted. Only licensed commercial entities can move cannabis derivatives across the border, which keeps the legal import and export channel narrow, controlled, and, at least in theory, easier for DIGEMID to monitor and audit.
Where the model gets thin is on the cultivation side. As of 2022, a single company, Cann Farm, held Peru's only cultivation-based production license, underscoring just how concentrated supply has been at the growing stage of the chain. That changed slightly in 2025: on February 13, 420 Green Cure received Peru's first associative cultivation license for medical cannabis. It's worth being precise about what that license actually represents, though. It's a patient-association model geared toward member access, not a commercial farming operation built for export-scale output. It expands who can legally grow, but it doesn't by itself create the volume an export business would need.
The clearest signal that companies have taken the export idea seriously came from Khiron Life Sciences, which previously announced intentions to export finished cannabis products manufactured in Peru into regional markets, Brazil among them. That announcement is a useful marker of industry ambition, and it lines up with the structural advantages Peru's law provides. Whether those announced plans have translated into consistent, ongoing shipments is a separate question, and one the public record doesn't clearly answer.
The Money and the Voices Behind the Push
Photo by Matheus Bertelli via Pexels.
The people closest to Peru's cannabis industry describe its trajectory in measured, incremental terms rather than breakout growth. Curt Schwarz, president of Asopecanna, the Peruvian Cannabis Industries Association, and CEO of Anden Naturals, has characterized the market as evolving steadily and positively rather than exploding. That's a notably restrained assessment from an industry advocate, and it tracks with what the licensing numbers show elsewhere in this piece.
Asopecanna estimates that Peru's domestic medical cannabis market moved more than S/8 million annually as of 2025. Put in perspective against the country's roughly 33 million people and its broader pharmaceutical sector, that's a modest figure, one that reflects a niche, still-forming market rather than an established industry generating substantial trade revenue.
Industry analysts view Peru's export potential with cautious optimism rather than certainty. Kacey Morrissey, speaking with the Peruvian business outlet Gestion, said Peru has significant potential to develop as an export platform for cannabis products, but was careful to frame that as a process that will still take time rather than something imminent. That caution is worth taking seriously, especially set against the fact that much of the export-hub narrative surrounding Peru dates back to coverage from 2019 through 2022, a period when companies and commentators discussed potential markets and planned shipments far more than confirmed, completed exports.
That's an important distinction for anyone trying to size up the sector today. Actual export volumes and dollar values from Peru's cannabis industry are not well documented in public reporting, and press coverage from that earlier period tended to describe intentions and licensing milestones rather than customs data or shipment records. Getting a real read on how much product Peru has actually exported, and to whom, likely requires pulling directly from DIGEMID's licensing and authorization records, from Asopecanna's own market data, or from PromPerú, the government trade promotion agency that tracks Peruvian exports across sectors. Journalism built on company announcements alone won't get you there.
What Has to Happen Next
Photo by Vien_beos via Pixabay.
Scaling exports from where Peru stands now means solving a production problem before anything else. Two active manufacturing labs and a single cultivation license holder simply can't generate the consistent volume that reliable export contracts require. Building out GMP-certified manufacturing capacity is the real bottleneck standing between Peru's export-friendly legal framework and any meaningful export business, and that's a capital-intensive, multi-year undertaking, not a licensing paperwork fix.
The demand side of the equation looks more promising, at least in theory. Brazil and other Latin American markets have repeatedly come up as potential buyers for Peruvian-made cannabis products, and Peru's finished-product model is well suited to serving that kind of cross-border demand if supply ever catches up. But interested buyers won't commit to Peruvian suppliers who can't guarantee consistent batches and proper sanitary registrations for the destination market. Export relationships get built on reliability, and reliability is exactly what a two-lab production base can't yet promise.
There's also a political and public-health tension that shouldn't be glossed over. With only about 34 percent of registered patients currently able to access product domestically, regulators and public opinion may resist any policy shift that appears to prioritize export capacity while Peruvians with medical cannabis registrations are still going without. Any credible path toward scaling exports probably needs to run in parallel with improving domestic access, not ahead of it, both as a practical supply matter and as a matter of political legitimacy for the whole program.
Timing adds another layer of uncertainty. Commentary tied to Peru's 2026 election season suggests cannabis policy is becoming a more visible topic in national political conversation than it's been in years. That visibility cuts both ways: it could bring renewed attention and reform momentum to a sector that's been quietly stalled since 2023's Supreme Decree, or it could just as easily stall further progress if the incoming political leadership treats cannabis as a low priority or a liability. Which way that goes will have more bearing on Peru's export future than anything written into the current regulation.
Peru has spent nearly a decade constructing what is, on paper, one of the most export-permissive cannabis frameworks in South America. Law 30681, its 2019 amendment, and the 2023 Supreme Decree together built a system that explicitly allows finished, packaged, consumer-ready cannabis products to move across borders, something Colombia's compounded-formula model doesn't permit. That's a genuine structural advantage, and it's the reason industry watchers have floated Peru as a future regional export hub since at least 2019.
But DIGEMID's March 2026 licensing data makes clear that the advantage is still theoretical. Two active production laboratories, one cultivation license holder, and a domestic patient base where two-thirds of registered users still can't get their hands on the product describes an industry in its infancy, not a launchpad ready to serve Brazilian or regional demand. The finished-product edge over Colombia only becomes meaningful once Peru has enough licensed, GMP-certified manufacturing capacity to fill export orders reliably and repeatedly, and that capacity simply doesn't exist yet at scale.
Whether Peru actually becomes the export platform that industry figures have been describing for six years now will come down to something fairly unglamorous: whether licensing, cultivation, and patient access all expand together over the next few years, rather than one racing ahead of the others. The law is already there. The industry, largely, is not yet.
